Harlan Robins Sells 8,120 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 8,120 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.00, for a total transaction of $154,280.00. Following the completion of the sale, the insider owned 1,179,524 shares in the company, valued at approximately $22,410,956. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Adaptive Biotechnologies Trading Down 4.8%

NASDAQ:ADPT opened at $16.47 on Friday. The company has a 50-day moving average of $17.10 and a 200-day moving average of $15.16. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -30.50 and a beta of 2.18. Adaptive Biotechnologies Corporation has a twelve month low of $6.26 and a twelve month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The business’s quarterly revenue was up 51.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.23) earnings per share. On average, research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

More Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — Adaptive reported EPS of ($0.09) vs. a consensus loss of ($0.19) and revenue of $71.7M vs. consensus ~$59.4M, showing stronger-than-expected commercial traction. MarketBeat Earnings Coverage
• Neutral Sentiment: Company published full Q4 and FY2025 financial results, slide deck and conference call materials for review — useful for modeling guidance and revenue composition but no new long‑term guidance announced in headlines. GlobeNewswire Press Release
• Neutral Sentiment: Analyst positioning remains mildly constructive (consensus “Moderate Buy” and an average price target near the mid‑teens), which can provide support if execution continues. Analyst Coverage Note
• Negative Sentiment: Insider selling: CEO Chad Robins disclosed sale of ~125k shares (~$2.3M at ~$18.44) and other insiders (Harlan Robins) sold additional shares this week — large insider sales can signal tax/liquidity moves but often weigh on near‑term sentiment. SEC Filing (Insider Sales)
• Negative Sentiment: Despite the beat, Adaptive remains unprofitable (negative net margin and ROE), and investors may be focused on the path to consistent profitability and cash flow; that concern likely contributed to the stock decline today. MarketBeat Company Snapshot

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Sigma Planning Corp lifted its position in shares of Adaptive Biotechnologies by 150.1% in the fourth quarter. Sigma Planning Corp now owns 32,550 shares of the company’s stock worth $529,000 after purchasing an additional 19,535 shares in the last quarter. Jennison Associates LLC grew its position in Adaptive Biotechnologies by 103.9% during the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after purchasing an additional 1,363,181 shares in the last quarter. Keybank National Association OH increased its stake in Adaptive Biotechnologies by 73.4% in the 4th quarter. Keybank National Association OH now owns 17,966 shares of the company’s stock valued at $292,000 after buying an additional 7,604 shares during the period. M&T Bank Corp purchased a new stake in Adaptive Biotechnologies in the 4th quarter worth approximately $350,000. Finally, Huntleigh Advisors Inc. boosted its stake in shares of Adaptive Biotechnologies by 5.6% during the 4th quarter. Huntleigh Advisors Inc. now owns 86,631 shares of the company’s stock valued at $1,407,000 after buying an additional 4,593 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 7th. BTIG Research boosted their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Piper Sandler boosted their price target on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.22.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.